A nurse is monitoring a patient for extrapyramidal symptoms. What medication strategy is essential to reduce the likelihood of these symptoms?

Choice A reason: Atypical, or second-generation, antipsychotics have a lower affinity for D2 receptors in the nigrostriatal pathway and a higher affinity for serotonin receptors. This pharmacological profile significantly reduces the risk of extrapyramidal symptoms (EPS) compared to first-generation medications, making them the preferred strategy for patients prone to motor side effects. Choice B reason: Adding more typical antipsychotics would exacerbate the blockade of dopamine receptors in the basal ganglia. Typical antipsychotics are the primary causative agents of EPS, and increasing the total burden of these medications would worsen muscle rigidity, tremors, and the risk of developing irreversible tardive dyskinesia for the patient. Choice C reason: While monitoring blood levels is important for some psychiatric medications like lithium or clozapine, most typical antipsychotics do not have a well-defined "therapeutic window" for blood levels that prevents EPS. The occurrence of EPS is more closely tied to receptor occupancy percentages than to simple systemic serum concentrations. Choice D reason: Increasing the dose of typical antipsychotics directly increases the occupancy of D2 receptors in the striatum. When occupancy exceeds 80%, the likelihood of EPS rises dramatically. Therefore, increasing the dose is the opposite of the required clinical strategy to manage or prevent the development of movement disorders.